CPA
MLYS icon

Capital Performance Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Capital Performance Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23
Closed -$279 – 1676
2024
Q3 		$279 Buy
+23
New +$278 ﹤0.01% 2482

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Capital Performance Advisors's MLYS Position: Q4 2024 in Review

Capital Performance Advisors sold out of Mineralys Therapeutics (MLYS) in Q4 2024, closing a stake of 23 shares — an estimated $279 sold.

Capital Performance Advisors first reported a position in MLYS in Q3 2024 and held it in 1 quarter. The position peaked at $279 in Q3 2024. 108 funds tracked by Wall St. Rank hold MLYS as of Q4 2024.

  • Capital Performance Advisors reported no remaining Mineralys Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 23 Mineralys Therapeutics shares in Q4 2024, an estimated $279.
  • Capital Performance Advisors first reported a position in Mineralys Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Mineralys Therapeutics position peaked at $279 in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.